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Background: The JAK2 V617F mutation is the most frequent somatic change in myeloproliferative neoplasms,
making it an important tumour-specific marker for diagnostic purposes and for the detection of minimal residual
disease. Sensitive quantitative assays are required for both applications, particularly for the monitoring of minimal
residual disease, which requires not only high sensitivity but also very high specificity.
Methods: We developed a highly sensitive probe-free quantitative mutant-allele detection method, Quantitative
Threefold Allele-Specific PCR (QuanTAS-PCR), that is performed in a closed-tube system, thus eliminating the
manipulation of PCR products. QuantTAS-PCR uses a threefold approach to ensure allele-specific amplification of
the mutant sequence: (i) a mutant allele-specific primer, (ii) a 3′dideoxy blocker to suppress false-positive
amplification from the wild-type template and (iii) a PCR specificity enhancer, also to suppress false-positive
amplification from the wild-type template. Mutant alleles were quantified relative to exon 9 of JAK2.
Results: We showed that the addition of the 3′dideoxy blocker suppressed but did not eliminate false-positive
amplification from the wild-type template. However, the addition of the PCR specificity enhancer near eliminated
false-positive amplification from the wild-type allele. Further discrimination between true and false positives was
enabled by using the quantification cycle (Cq) value of a single mutant template as a cut-off point, thus enabling
robust distinction between true and false positives. As 10,000 JAK2 templates were used per replicate, the assay had a
sensitivity of 1/10-4 per replicate. Greater sensitivity could be reached by increasing the number of replicates analysed.
Variation in replicates when low mutant-allele templates were present necessitated the use of a statistics-based
approach to estimate the load of mutant JAK2 copies. QuanTAS-PCR showed comparable quantitative results when
validated against a commercial assay.
Conclusions: QuanTAS-PCR is a simple, cost-efficient, closed-tube method for JAK2 V617F mutation quantification that
can detect very low levels of the mutant allele, thus enabling analysis of minimal residual disease. The approach can
be extended to the detection of other recurrent single nucleotide somatic changes in cancer.
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Myeloproliferative neoplasms (MPN) are clonal hema-
topoietic stem cell malignancies comprising several di-
verse pathologies. The 2008 World Health Organization
(WHO) classification incorporated JAK2 V617F mutation
status into the diagnosis of BCR-ABL negative MPN [1].
This mutation is the most frequent somatic change in
MPN, occurring in over 95% of patients with polycy-
themia vera (PV) and in 50% of patients with essential
thrombocythemia (ET) or primary myelofibrosis (PMF)
[2]. The valine to phenylalanine substitution at amino acid
617 causes a disruption of the auto-inhibitory JH2 domain
of JAK2, leading to constitutive activation of the JAK2
tyrosine kinase activity and a consequent loss of control
in cell proliferation and growth [3,4]. Small-molecule in-
hibitors targeting JAK2-driven cancers have recently en-
tered clinical trials [5,6].
The JAK2 V617F change results from the c.1849G > T
point mutation in exon 14 of the JAK2 gene (COSMIC
ID: COSM12600). Numerous detection methods for the
JAK2 c.1849G > T mutation have been published in-
cluding, restriction fragment length polymorphism ana-
lysis, Sanger sequencing, pyrosequencing, amplification
refractory mutation system, allele-competitive blocker
PCR, and melt curve analysis or high resolution melting
(HRM) [7-20].
For the detection of minimal residual disease, highly
sensitive quantitative assays are required. Several quanti-
tative PCR methods based on mutation-specific primers
or probes or LNA-modified oligonucleotides have been
developed [21-27]. These range in sensitivity from me-
dium (0.1-1% mutant alleles) to high (< 0.1% mutant al-
leles). Less sensitive assays (with a detection limit of 1-3%
mutant alleles) are useful for disease diagnosis [28].
In the minimal residual disease context, the detection
of low levels of the mutation can be challenging, es-
pecially due to the occurrence of false positives. Thus,
accurate and sensitive V617F testing of treated MPN pa-
tient samples needs to be performed using assays that
minimise or at least enable the recognition of false posi-
tives. For these purposes, we developed a new highly
sensitive assay, based on allele-specific PCR, which is
able to specifically and efficiently suppress amplification
of the wild-type allele.
The method that we developed, QuanTAS-PCR, is a
probe-free quantitative PCR method based on a three-
fold approach to ensure specific amplification of the
mutant JAK2 allele: (i) the use of allele-specific primers to
amplify the mutant allele (sometimes known as allele-
specific PCR or ARMS), combined with (ii) the use of
a non-extendible dideoxy oligonucleotide complementary
to the wild-type allele and known as a blocker, and (iii)
the use of a PCR specificity enhancer. By combining these
three measures, we achieved high analytical sensitivity(one single mutant allele per well) coupled with high ana-
lytical specificity, providing a robust quantitative assay.
Methods
Patients and controls
This study was covered by an approval from the Peter
MacCallum Cancer Centre Ethics Committee (project
number 03/90). DNA from 27 peripheral blood samples
and 11 bone marrow aspirates of patients with a suspected
diagnosis of myeloproliferative neoplasms had originally
been used for diagnostic testing using our previously
reported JAK2 assay [17]. Normal controls included thir-
teen anonymised blood samples obtained from the Aus-
tralian Red Cross Blood Service as well as an additional
blood sample taken under informed consent. The human
erythroblast leukemia cell line HEL, which bears a homo-
zygous JAK2 V617F mutation, was used as a source of
100% mutant DNA. The human promyelocytic leukemia
cell line HL-60 was used as a source of 100% wild-type
DNA.
DNA extraction
DNA was extracted using either the DNeasy blood
and tissue kit (Qiagen, Hilden, Germany) or the Wizard
Genomic DNA Purification kit (Promega, Madison, WI)
as per the manufacturer’s instructions. DNA quantifica-
tion was performed using the Qubit dsDNA HS Assay
kit and the Qubit 2.0 Fluorometer (Life Technologies,
Carlsbad, CA). The Qubit readings were used as a guide-
line for dilution of the DNA samples.
Dilution series for mutant allele quantification
A set of mutant allele dilutions was prepared by mixing
quantification cycle (Cq) normalised HEL DNA (MUT)
which harbors the mutant allele only, and HL-60 DNA
(WT), which harbors the wild-type allele only. In earlier
experiments, the HEL DNA (MUT) had been normalised
for their JAK2 copy number, based on their amplification,
and mixed with genomic DNA extracted from a healthy
blood donor (WT). Each MUT/WT mix was made to a
final DNA concentration of 16.5 ng/μl, which corresponds
to a total number of 5,000 JAK2 copies/μl.
The number of JAK2 copies/μl was calculated on the
basis that one diploid human cell contains approxi-
mately 6.6 pg of DNA and therefore 33 ng human gen-
omic DNA contains approximately 10,000 copies of each
diploid gene. The mixes contained a decreasing propor-
tion of the mutant allele relative to the wild-type allele,
as follows: 30%, 10%, 3%, 1%, 0.3%, 0.1%, 0.03% and
0.01%. The 100% mutant and the 100% wild-type control
DNA samples were included in each PCR. For quality
control, the total JAK2 copy number of each MUT/WT
mix was tested by running the JAK2 exon 9 PCR, using
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at http://LinRegPCR.nl.
JAK2 exon 9 PCR: normalisation for JAK2 copy number
Normalisation of the JAK2 copy number is required for
accurately creating a dilution series. We amplified an 85
bp amplicon from exon 9 of the JAK2 gene (GenBank
accession number EF194100). Reactions were carried out
in white 96 well LightCycler 480 Multiwell Plates on the
LightCycler 480 (Roche Diagnostics, Penzberg, Germany)
in a 10 μl final reaction volume comprising 1X PCR Buffer
(Qiagen) containing 1.5 mmol/L of MgCl2, 200 μmol/L of
each deoxynucleotide triphosphate (Fisher Biotec, Perth,
Australia), 400 nmol/L of the forward primer and 200
nmol/L of the reverse primer (JAK2_Ex9_F: 5′-TTAAC
TGCAGATGCACATCATTACCT-3′ and JAK2_Ex9_R: 5′-
GGCCATGACAGTTGCTTTGTATATT-3′) (GeneWorks,
Adelaide, Australia), 5 μmol/L of SYTO 9 (Invitrogen,
Carlsbad, CA), 0.25 units of HotStar Taq DNA polymerase
(Qiagen).
2 μl of template was used at a concentration of 16.5 ng/
μl, which corresponded to a total of about 10,000 JAK2
copies per reaction.
The PCR conditions included an initial denaturation
of 15 minutes at 95°C, followed by 60 cycles of 20 sec-
onds at 94°C (when run along with the V617F mutation
assay; 55 cycles when run by itself for quantification), 40
seconds at 63°C, 30 seconds at 72°C; 1 cycle of 1 minute
at 95°C, 1 minute at 45°C, and a high resolution melting
(HRM) step from 65°C to 95°C, increasing at 0.2°C per
second. The HRM step was included as a quality control
step to identify non-specific amplification.
Both the 100% mutant and the 100% wild-type con-
trols were normalised for JAK2 copy number in order to
begin with equivalent numbers of amplifiable JAK2 tem-
plates. The two cell lines were normalised against DNA
obtained from a normal peripheral blood sample which
was used as Cq reference based on its high quality and
diploidy. LinRegPCR 12.5 software was used to deter-
mine the Cq values obtained from the normal peripheral
blood DNA and from the HEL and HL-60 DNA control
samples. The resulting values were used to adjust the
concentration of each DNA, so that each had equivalent
numbers of amplifiable JAK2 templates.
QuanTAS-PCR
The quantitative PCR method developed in this study
consists of two PCR assays; a mutation-specific assay and
an exon 9 copy number normalising reference assay (as
already described above). For the detection of the JAK2
exon 14 V617F mutation, the mutant allele-specific com-
petitive blocker assay amplifies only the mutant allele.
The JAK2 V617F mutation PCR assay was designed com-
plementary to the sense strand for the region framing theV617F mutation on JAK2 exon 14. It consists of three
oligonucleotides. The first is a mutant allele-specific for-
ward primer JAK2_Ex14_Mut_F: 5′-CTTACTCTCGTC
TCCACAGAA-3′ (where the bold “A” marks the position
of the V617F nucleotide substitution). The second is the
reverse primer JAK2_Ex14_R: 5′-TTCCTTAGTCTTTCT
TTGAAGCAG-3′ resulting in an amplicon that is 101 bp
in length. The third is a blocker oligonucleotide with
a dideoxycytidine (ddC) at its 3′ end: JAK2_Ex14_WT_
Blocker_F: 5′-CTTACTCTCGTCTCCACAGA-ddC-3′
(Sigma Aldrich, St. Louis, MO, USA).
The dideoxy blocker competes with the mutant allele-
specific forward primer and preferentially anneals to
wild-type templates. Extension of the 3′ dideoxy oligo-
nucleotide is not possible. The dideoxy blocker sup-
presses false-positive amplification by outcompeting the
forward mutant allele-specific primer for binding to the
wild-type template (Figure 1).
The JAK2 mutation-specific PCR reactions were
performed in a 10 μl final volume comprising 1X PCR
Buffer containing 1.5 mmol/L of MgCl2, 0.5 mmol/L of
extra MgCl2 (for a final concentration of 2 mmol/L of
MgCl2), 200 μmol/L of each deoxynucleotide triphos-
phate, 200 nmol/L of the JAK2_Ex14_WT_Blocker_F
oligo, 400 nmol/L of the JAK2_Ex14_Mut_F primer, 200
nmol/L of the JAK2_Ex14_R primer, 5 μmol/L of
SYTO9, 1X Q-Solution (Qiagen), 0.25 units of HotStar
Taq DNA polymerase and 2 μl of template (at a concen-
tration of 16.5 ng/μl), for a total of about 10,000 JAK2
copies per reaction. Early experiments did not include
the Q-Solution PCR specificity enhancer.
The JAK2 exon 9 PCR was used as a reference assay
since it amplifies every JAK2 allele present in the reac-
tion. The JAK2 exon 9 PCR was run along with each
JAK2 V617F mutation-specific PCR, in order to normal-
ise each sample for its input number of JAK2 templates,
thus enabling accurate quantification of JAK2 mutant
templates.
Reactions were carried out in white 96 or 384 well
LightCycler 480 Multiwell Plates on the LightCycler 480
and both PCR assays were run simultaneously under the
following optimised conditions: an initial denaturation of
15 minutes at 95°C, followed by 60 cycles of 20 seconds
at 94°C, 40 seconds at 63°C, 30 seconds at 72°C; 1 cycle
of 1 minute at 95°C, 1 minute at 45°C and a HRM step
from 65°C to 95°C increasing at 0.2°C per second. The
HRM step was included as a quality control step to iden-
tify non-specific amplification.
For the JAK2 exon 9 reference assay all samples were
run in duplicate or triplicate (depending on the total
amount of DNA available for each sample). We used 33
ng of DNA per reaction, which corresponds to 10,000
JAK2 copies/well in the case of a high quality DNA
preparation. (It is important to note that for low-quality/
Figure 1 Representation of the mutant allele-specific PCR and 3′ dideoxy blocker oligonucleotide methodology. Two PCR primers, a
mutant allele-specific forward primer and a reverse primer, are present in each reaction. In addition, a forward wild-type allele-specific dideoxy
blocker (designated WT blocker), which binds to the wild-type allele but is incapable of extension, is present. It will outcompete the forward
mutant allele-specific primer (designated MUT specific) for binding to the wild-type template and, coupled with the already low rate of
amplification of a mutant allele-specific primer from a wild-type template, will further reduce the rate of false-positive amplification.
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be applied to reach the same total JAK2 copy number, as
the amplifiable templates will be fewer in number. This
can be monitored using the JAK2 exon 9 reference assay
and comparing the Cq of any high quality diploid gen-
omic DNA preparation to the Cq of the low-quality/de-
graded samples tested.)
Samples were run in triplicate for the JAK2 mutation-
specific PCR. If any of the 3 replicates showed no ampli-
fication, we repeated the assay by running 10 replicates
of that specific sample. The low-mutation-level mixes
(MUT/WT 0.03% and 0.01%) were always run in repli-
cates of 10. Using an increased number of replicates for
the low concentration samples firstly allowed us to have
a reliable reference for the Cq value obtainable from one
single copy of the mutant allele and secondly, produced
an increased amount of data which facilitated the use
of a statistics-based approach for the estimation of the
average mutant JAK2 copy number (see below). The nega-
tive control samples (genomic DNA from healthy blood
donors and cell lines DNA samples) were run in at least
10 replicates.
Real-time data analysis
The real-time PCR data were analysed using LinRegPCR
12.5 software. The raw run data (not-baseline-corrected)
for both the JAK2 exon 9 PCR (reference assay) and the
JAK2 mutation-specific PCR were transferred from the
LightCycler 480 to the LinRegPCR 12.5 software using
the “LC480 Conversion: conversion of raw LC480 data”
software (available on the Heart Failure Research Center
website, at http://downloads.hfrc.nl, and treated as two
different data sets (amplicon groups).
The LinRegPCR program performs sample by sample
baseline correction, and finds a “window-of-linearity” for
each amplicon group. This software uses linear regres-
sion to fit a straight line through each set of amplifica-
tion curves: the slope of this regression line gives the
PCR efficiency for each individual sample. It also esti-
mates the “mean PCR efficiency” (E) for each amplicon
by calculating the mean value of all sample efficiencies
obtained per amplicon group. In performing the meanefficiency per amplicon calculation, the software was
manually set to automatically exclude efficiency values
deviating more than 5% from the median efficiency and
samples which did not show amplification.
The data were first analysed using the automated
LinRegPCR functions and subsequently manually corrected
where required (as suggested by the LinRegPCR user man-
ual, version 12.x). The fluorescence quantification threshold
(Nq) was set to “common” for the JAK2 exon 9 and JAK2
exon 14 amplicon groups.
The LinRegPCR software uses the Nq value and the
fractional cycle number (Cq) (needed for each sample to
reach the Nq threshold) to calculate the starting concen-
tration (N0) of each target (expressed in arbitrary fluor-
escence units), according to the equation N0 = Nq/E
Cq.
The N0 values obtained for each sample and for the
100% mutant control (HEL DNA), for both the JAK2
exon 9 control assay and the JAK2 exon 14 test assay are
then used to calculate the JAK2 mutant load for each of
the sample replicates, as described by the equation:
Mut % ¼
Ex14ð Þ Individual sample replicates N0 value
Ex9ð Þ Average sample replicates N0 value
Ex14ð Þ Average 100%Mutant replicates N0 value
Ex9ð Þ Average 100%Mutant replicates N0 value
100
The numerator in this formula measures the mutant
(exon 14) to total (exon 9) JAK2 ratio for a given sample,
and the denominator normalises this value by calculating
the same ratio for the 100% JAK2 mutant control.
The formula allowes the monitoring of possible varia-
tions within the resulting mutation burden values of the
replicates of each sample. The mean JAK2 mutant-allele
burden per sample was calculated by averaging the indi-
vidual percentage for each replicate of that sample, ex-
cluding any obvious outlier values.
Criteria to minimise the scoring of false positives
We then aimed to develop criteria to minimise the scor-
ing of false positives. For this, it was necessary to iden-
tify the Cq value given by the amplification of a single
mutant allele. Running 10 replicates of the 0.01% MUT/
WT mix in each PCR run allowed us to have a reliable
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copy of the mutant allele, which was then used as a
guideline for the identification of rare false-positive oc-
currences. Signals that amplify significantly later are
considered to be false positives, as it is not possible to
have a template number between 1 and 0.
Samples with very low numbers of mutant alleles
Samples with very low numbers of mutant alleles presented
a particular challenge for quantification. In these samples,
















Figure 2 The sensitivity of QuanTAS-PCR for quantifying JAK2 mutant
JAK2 exon 9 reference qPCR shown in panel B were run simultaneously (ra
containing different percentages of mutant allele in a background of wild-
entire standard curve (prepared as described in the Methods) are shown. A
100%), the mutant in wild-type mixes (MUT/WT) 10%, 1% and 0.1% and the
type mix MUT/WT 0.01% and the 100% wild-type control (WT 100%) were
amplified very late (LinRegPCR-calculated Cq = 58.2) compared to a single c
considered negative for the V617F mutation. The NTC did not amplify, as e
normalisation. Each sample was run in triplicate. The graph shows that all s
amplify, as expected.the replicates due to stochastic variation in the number of
mutant alleles present per well. For example, if the aver-
age number of copies per replicate is 1 (i.e 1 mutant allele
in the typically 10,000 alleles tested per well), there may
be 0, 1, 2, or rarely more than 2 copies in a given replicate
(in accordance with Poisson distribution).
For low copy number replicates which show multiple
wells with no amplification, it is possible to determine
when a single mutant JAK2 copy has been amplified
(Figure 2). A single copy will have the lowest possible
Cq value that is achievable for a true positive. Twoalleles. The JAK2 mutation-specific qPCR shown in panel A and the
w data (not baseline corrected) are shown). A range of samples
type allele were tested. For simplicity, only selected dilutions of the
: JAK2 mutation-specific PCR. The 100% mutant control DNA (MUT
no template control (NTC) were run in triplicate. The mutant in wild-
run in 10 replicates. One of the 10 WT 100% replicates (in blue colour)
opy at 56.2. This represents a typical false positive and the sample was
xpected. B: JAK2 exon 9 reference qPCR used for DNA input and
amples had an equivalent number of JAK2 templates. The NTC did not
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tional to the amplification efficiency of the assay. As our
JAK2 mutation-specific assay typically has an amplifica-
tion efficiency approximately equal to 1.7, this will be
close to 1 Cq earlier. The probabilities of occurrence of
each of the counts, y, can be modeled as a modified ver-
sion of the Poisson distribution (right-censored Poisson
distribution) with mean copy number, λ. The possible
outcomes for more than two copies are grouped to-
gether as a single observation type, as we are unable to
resolve these further. The probabilities for the number
of JAK2 V617F copies in a given experiment are calcu-
lated as described by the formula:











The value of lambda (λ) represents the average copy
number of mutant JAK2 alleles assessed per replicate
(e.g. the standard curve mix MUT/WT 0.03% will con-
tain an average copy number λ = 3, when testing 10,000
JAK2 copies per tube). The formula consists of two com-
ponents. The first component (y ≤ 2) describes the
Poisson distribution probability of observing y = 0, 1 or 2
copies of mutant JAK2. The second component (y > 2)
describes the Poisson distribution probability of observ-
ing more than 2 copies of mutant JAK2. The probability
of observing more than 2 copies is given as one minus
the probabilities of observing 0, 1 and 2 copies.
A point estimate of the average number of mutant JAK2
copies was obtained as the value of λ that maximises the
likelihood of this distribution, given the observed number
(y) of mutant JAK2 copies in each experimental replicate
(see formula above). The associated 95% confidence inter-
val was obtained finding the values of λ for which the
application of the likelihood test would not reject the
null hypothesis of λ ≠ λ0, where λ0 is the value lambda
found by the maximum likelihood-based method de-
scribed above. These calculations were performed using
the R statistical computing software v2.141.0 [31]. The
relevant code is provided (Additional file 1).
Results
The use of high resolution melting (HRM) as a quality
control step
The exon 9 and the JAK2 V617F mutation-specific PCR
assays use probe-free real-time amplification with a fluor-
escent intercalating dye (SYTO 9) to enable both quantifi-
cation and HRM. The dye binds to double stranded DNA
specifically and fluoresces only when intercalated. The
HRM step allows the ready identification of any non-
specific amplification, such as primer dimers or non-targeted sequences, both during optimisation experiments
and routinely as a quality control for all experiments. Use
of HRM in preference to gel electrophoresis both im-
proves the workflow and eliminates PCR product ma-
nipulation as HRM is performed in the same reaction
vessel immediately after the real-time amplification (often
described as a closed-tube system).
While we did not see primer dimers, non-specific
amplification was occasionally seen during the opti-
misation experiments. Figure 3 (panel A) shows an ex-
ample of non-specific amplification. It should however
be noted that false-positive amplification due to mutant
primers binding to wild-type templates will not be dif-
ferentiated from true positive amplification by means
of HRM analysis.
The use of a 3′ dideoxy blocker
The 100% mutant and 100% wild-type controls were
normalised to the same amplifiable JAK2 copy number
using the exon 9 assay. Significant false-positive amplifi-
cation from the wild-type template was observed without
the 3′ dideoxy blocker (see Figure 4; panel A). With the
dideoxy blocker, there was an improvement but still con-
siderable false-positive amplification (see Figure 4; panel B).
Although the introduction of the dideoxy blocker might
have been expected to completely suppress false-positive
amplification from the wild-type template, the false-
positive amplification still detected was probably due to the
occasional annealing of the mutation-specific forward pri-
mer to wild-type templates. Increasing the concentrations
of the dideoxy blocker did not improve the overall assay
results.
Increased specificity with the use of Q-Solution
We tested the effect of using the proprietary PCR speci-
ficity enhancer Q-Solution (Qiagen) in addition to the
dideoxy blocker to test whether we could further reduce
false-positive amplification from wild-type templates. Q-
Solution was added to the JAK2 mutation-specific PCR,
both with and without the dideoxy blocker. We found
that the use of Q-Solution alone increased the analytical
specificity of the assay, reducing the early occurrence of
false positives, possibly by decreasing the chance of
false-priming. Nevertheless, we found that false positives
could (very rarely) occur at relatively early Cq values
with the use of Q-Solution alone (see Figure 4; panel C
for an example of this). When we added the dideoxy
blocker to the Q-Solution, we observed an even greater
Cq value differential between the controls and the false
positives (see Figure 4; panel D). Therefore, the com-
bined use of the 3′ dideoxy blocker and Q-Solution in
QuanTAS-PCR was our chosen approach for reducing
false positives. However, it should be noted again that

















Figure 3 HRM as a quality control step. The use of an intercalating dye rather than a fluorescent probe to monitor the reaction allows the
addition of an HRM step to identify non-specific amplification. Samples tested: 100% mutant control DNA (MUT 100%) analysed in triplicate, 100%
wild-type control DNA (WT 100%) analysed in 10 replicates, non-template control (NTC) analysed in triplicate. A. JAK2 V617F mutation-specific PCR
high resolution melting. The NTC amplification product melted at a temperature clearly different (higher) than that of the targeted sequence,
showing this was a case of non-specific amplification. It is important to note that the WT 100% amplification deriving from non-specific annealing
of the mutant-specific forward primer to wild-type templates cannot be distinguished by HRM. B. JAK2 exon 9 PCR high resolution melting. All
PCR products show the same melting profile, indicating no presence of non-specific amplification products. C. JAK2 V617F mutation-specific PCR
amplification (early experiment, no Q-Solution was used). One of the NTC replicates amplified at a Cq value of about 54.6 and multiple WT 100%
replicates amplified at Cq values that ranged from 46.5 to 58. D. JAK2 exon 9 PCR amplification, performed to check for DNA input and
for normalisation.
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ditions, and thus the Cq differential may not be an ac-
curate guide to the differences between the assays.
The addition of Q-Solution resulted in a decrease in
amplification efficiency, which can be explained by a
shift of the annealing equilibrium between primers and
template. The loss of PCR efficiency and the consequent
increase in the Cq values of all the amplified samples did
not impair the assay’s analytical sensitivity. Similar re-
sults were obtained with betaine which is likely to be the
principal component of Q-Solution, but this was not ex-
plored further.Optimisation of DNA input
In order to design a quantitative PCR assay that could
comfortably detect a very low mutant to wild-type ratio,
we established the optimum amount of the DNA re-
quired. This was to avoid high amounts of genomic DNA
resulting in PCR inhibition or strong background noise,
while keeping the template number as high as possible.
We carried out a comparative assay, analysing the differ-
ent sensitivities obtained when 33, 66, 99 or 198 ng/well
of DNA were used (corresponding respectively to 10,000JAK2 copies/well, to 20,000 JAK2 copies/well, to 30,000
JAK2 copies/well and to 60,000 JAK2 copies/well).
The detection of mutant alleles at a sensitivity of one
mutant allele copy per replicate was best achieved when
testing 33 ng of DNA per well (corresponding to 10,000
JAK2 copies/well). The results were concordant, both
with and without the addition of Q-Solution to the reac-
tions containing the dideoxy blocker. At higher DNA
amounts per well, we observed a proportional increase
in background noise in the amplification curves which
were not quantifiable using the LinRegPCR software,
and did not improve the assay sensitivity. No significant
background noise was observed when 33 ng of DNA
were used, enabling the LinRegPCR analysis to be readily
performed (Additional file 2).Criteria for the identification of false positives
Visual examination of replicates of the 0.01% and 0.03%
MUT/WT mixes in each run allowed us to identify the
Cq value of a single copy of the mutant allele, which was
then used as a guideline for the identification of rare
false positives. Samples that amplified 2 or more cycles
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Figure 4 Increasing the assay specificity of the JAK2 V617F mutation-specific PCR. Samples tested: 100% mutant control DNA (MUT 100%)
analysed in triplicate, 100% wild-type control DNA (WT 100%) analysed in 10 replicates, non-template control (NTC) analysed in triplicate. A.
Mutant allele-specific PCR. The reactions contained two oligonucleotides: the mutant allele-specific forward primer and the reverse primer. The
graph shows a significant number of false-positive amplifications. We observed a Cq value difference of 20 cycles between the MUT 100% and
the first false-positive amplification. B. Mutant allele-specific PCR with the introduction of the wild-type specific 3′ dideoxy blocker. The reactions
contained three oligonucleotides: the mutant allele-specific forward primer, the wild-type allele specific blocker and the reverse primer. The graph
still shows the presence of a number of false positives. We observed a Cq value difference of 23 cycles between the MUT 100% and the first
false-positive amplification. C. Mutant allele-specific PCR with the introduction of 1X Q-Solution. The reactions contained two oligonucleotides:
the mutant allele-specific forward and the reverse primers. The graph shows a significant reduction of false-positive amplifications to a single false
positive. We observed a Cq value difference of 16 cycles between the MUT 100% and the first false-positive amplification. D. Mutant allele-specific
PCR with the introduction of both the 3′ dideoxy blocker and 1X Q-Solution. The reactions contained three oligonucleotides: the mutant allele-
specific forward primer, the wild-type allele-specific blocker and the reverse primer. One false-positive amplification was observed, at a very late
Cq value. We observed a Cq value of 23 cycles difference between the MUT 100% and the first false-positive amplification.
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of less than one template.
Testing of negative controls
A total number of 13 “negative” control DNA samples
from randomly selected, healthy blood donors were
tested. Each sample was confirmed to be operationally
negative for the JAK2 V617F mutation by testing 10 rep-
licates. Each showed no positives in all replicates when
assessed with QuanTAS-PCR. Occasionally we observed
one replicate out of the 10 amplifying at a very late Cq
value, significantly later than the Cq value for the ampli-
fication of a single mutant allele copy.
In order to generate a standard series of controls, a
JAK2 V617F mutation-negative cell line was required.
We chose the HL-60 cell line, given that this cell line
(and the V617F mutant allele positive HEL cell line) are
readily available. We tested 60 replicates of HL-60 DNA
using QuanTAS-PCR at the optimised conditions to ver-
ify that it was truly negative for the mutation. Only 1
replicate out of 60 showed any amplification. However,
this was at a LinRegPCR-calculated Cq value equal to
58.2 (Figure 2; panel A), whereas on the same PCR run,
one single copy amplified at a LinRegPCR-calculated
Cq value of 56.2, and thus could be easily determined
to be an artefactual false positive. These results were
confirmed by analysing our data using the maximum
likelihood-based method (described in the Methods).
According to the statistical analysis, the WT 100% DNA
extracted from the HL-60 cell line was estimated to have
an average JAK2 copy number of 0.016 (confidence
interval 0.001 - 0.073) per reaction input. Since this
value is considerably less than one, we can confidently
regard such late amplification as a false positive. Thus
HL-60 was confirmed to be a suitable 100% wild-type
control.
Analytical sensitivity
In order to assess the analytical sensitivity of the
QuanTAS-PCR assay, a set of mutant/wild-type mixes
were prepared by mixing Cq normalised HEL DNA
(MUT) and HL-60 DNA (WT). Samples with the JAK2
V617F mutant allele present at levels of 100%, 30%, 10%,
3%, 1%, 0.3%, 0.1%, 0.03%, 0.01% were tested as well as
the 100% wild-type control. The assay showed an analyt-
ical sensitivity of one mutant allele per well (Figure 2;
panel A).
When testing the 0.03% and 0.01% mixes (ten replicates
each), we also calculated the average JAK2 copy number
for each replicate. We obtained a value of 2.00 copies
(confidence interval 1.20 - 3.10) for the 0.03% mix and a
value of 0.60 (confidence interval 0.24 - 1.22) for the
0.01% mix. Both estimations can be considered suffi-
ciently accurate, when compared to their correspondingexpected values equal to 3 and 1 allele copies per well
respectively.
Validation of mutant allele quantification in clinical
samples
DNA from 38 patients that had previously been tested
by the less sensitive ACB-PCR assay [17] was tested in a
blinded fashion using QuanTAS-PCR at the optimised
conditions. As expected from the analytical sensitivity
experiments, QuanTAS-PCR identified more positive
samples than the qualitative ACB-PCR assay (Additional
file 3). Five samples that were scored as negative for the
V617F mutation by the ACB-PCR assay were found to
be positive when tested with the QuanTAS-PCR, with
calculated mutant allele burdens that ranged from 2.03%
to 0.13% (namely 2.03%, 0.27%, 0.23%, 0.13% and 0.13%).
QuanTAS-PCR showed improved repeatability, showing
highly consistent Cq values within triplicate reactions. In
contrast, ACB-PCR showed a mix of signal intensities
within the replicates of seven samples, with some repli-
cates being strongly positive and others weakly positive
or even negative for the V617F mutation when PCR prod-
ucts were resolved on an agarose gel (Additional file 3).
The JAK2 mutation levels of 24 selected samples (all
of which had tested positive for the mutation using
QuanTAS-PCR) were also tested with the commercial
quantitative kit “JAK2 MutaQuant” (Ipsogen SA, Marseille,
France). The two assays showed comparable results, with a
coefficient of determination (R2) equal to 0.99 (Figure 5).
QuanTAS-PCR scored two samples as having averaged
mutant allele burden values equal to 113.7% and 148.7%.
Values greater than 100% can occur occasionally with
normalised real-time PCR data. In these two cases we
scored and plotted the samples as 100% mutant (Add-
itional file 3).
Discussion
Whereas for diagnostic purposes, an analytical sensitivity
of 1% is generally sufficient, minimal residual disease
studies require greater sensitivity, specificity and accur-
ate quantification. Many JAK2 V617F mutation detection
methodologies have been developed and published over
the last few years, only some of which are applicable to
minimal residual disease [7-11,13-18,21-27].
A recent multicenter study established that only two
of the eleven tested methods, both based on TaqMan
allele-specific qPCR, could reliably achieve an analytical
sensitivity of 0.2% [32]. However, it was more recently
reported that these two assays have problems with false-
positive results, whereas an alternative Locked Nucleic
Acid (LNA) based qPCR method showed a sensitivity of
0.4% [22].
A two step PCR method that claimed an analytical
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Figure 5 Regression analysis of the mutant allelic percentages
of 24 clinical samples determined using the “JAK2 MutaQuant”
assay (Ipsogen) (on the x axis) and QuanTAS-PCR assay (on the
y axis).
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based wild-type blocking system, whilst the subsequent
PCR step was an allele-specific qPCR to quantify the mu-
tant allele. The claimed sensitivity is unlikely as the sensi-
tivity of any methodology is limited by the number of
templates initially used in the assay. This sensitivity could
only be reached beginning with 100,000 templates or 300
ng of DNA in the tube. In addition, the first enrichment
step will prevent this method from being truly quantita-
tive. Furthermore, any two step approach (even one which
has a limited number of amplification cycles in the first
step) increases the risk of cross-contamination between
samples when performing the second step.
We developed a novel single-tube, single-step, mutant
allele-specific quantitative PCR assay: QuanTAS-PCR
(Quantitative Threefold Allele-Specific PCR) assay. It uses
a combination of established and novel features. We com-
bined the basic principles of (i) the use of a 3′mismatched
primer in allele-specific PCR, [33], (ii) of a wild-type
blocker [34] and (iii) we introduced the use of a PCR spe-
cificity enhancer.
In allele-specific PCR, the 3′ end of the mutant allele-
specific primer is placed over the mutation site, so that
mutant templates are preferentially amplified [35]. How-
ever, as numerous investigators have found, extensions
from the wild-type allele do still occur at low frequen-
cies. Mutant-specific amplification is enhanced by the
addition of a wild-type blocker to the PCR reaction [34].
A wild-type blocker is an oligonucleotide complemen-
tary to the wild-type allele with its 3′ end placed over
the mutation site. The blocker also bears a 3′ modifi-
cation which is incapable of 3′-5′ extension, therefore
“blocking” the wild-type allele amplification. In our as-say, we used a 3′dideoxycytidine oligonucleotide blocker
complementary to the sense strand where the wild-type
sequence terminates at the G at position 1849.
Dideoxy blockers are oligonucleotides bearing a dideoxy
nucleotide (ddNTP) at their 3′ ends. Dideoxy nucleo-
tides are effective chain terminators used in Sanger sequen-
cing [36]. ddNTPs are essentially deoxyribonucleotides
(dNTPs) without a 3′-hydroxyl group (-OH) on their de-
oxyribose sugar. Therefore 3′ddNTPs are unable to form
a phosphodiester bond with any other dNTP and chain
elongation is not possible.
A combination of allele-specific PCR and dideoxy
oligonucleotide blockers was first reported for the ana-
lysis of disease causing mutations in several genes [37]
but seems not to have been widely adopted. However,
there are major differences between the previous meth-
odology and the one reported here, including the use of
qPCR rather than endpoint PCR.
We enhanced the analytical specificity of the mutation-
specific assay by adding a proprietary co-solvent, Q-
Solution, to the PCR reaction. This increased the PCR
specificity of the JAK2 mutation-specific assay, showing
a further decreased occurrence of false-positive results
when compared to the same assay run without Q-
Solution. To the best of our knowledge, this is the first
application of the use of a co-solvent to increase speci-
ficity for the detection of minimal residual disease. Im-
portantly, the addition of a PCR specificity enhancer to
the PCR reaction is more efficient in suppressing false-
positive amplification from wild-type templates than the
addition of a dideoxy blocker. By combining the use of
a dideoxy blocker and a PCR specificity enhancer, we
achieved high analytical sensitivity (one single mutant-
allele per well) coupled with high analytical specificity,
providing a robust quantitative assay.
Another unique feature of our methodology is the com-
bined normalisation for the input of DNA and correction
for copy number variation by calibrating directly to the
JAK2 copy number in a control PCR (JAK2 exon 9 PCR),
using efficiency-corrected calculation of the starting con-
centrations per sample. This reference PCR was used for
each sample including the controls, allowing accurate
quantification of the mutant allele burden.
The use of real-time PCR technology allowed us to dis-
tinguish false-positive amplifications from true positive
ones, by determining the Cq value at which each sample
replicate was amplified with the JAK2 mutation-specific
assay. We were able to readily identify false positives
based on their high Cq values. False-positive samples are
those that clearly amplify later than the reactions starting
with a single copy of the template.
The quantitative JAK2 exon 9 and mutation-specific
PCR assays are designed to enable both real-time amplifi-
cation analysis and HRM analysis in the one run on a real-
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dye which does not inhibit PCR reactions when used at
saturating conditions [38], binds double stranded DNA
specifically and fluoresces only when intercalated. The use
of a closed-tube method like the QuanTAS-PCR is desir-
able in a diagnostic setting, being quicker, more reliable,
and able to minimise PCR carry-over problems.
When testing a sample that is expected to have very
low levels of mutant JAK2 alleles (below 0.03%), we
recommend using additional replicates, and analysing
the data using a statistical estimation approach such as
the maximum likelihood-based method described in the
Methods section. As a reference, 10 replicates of the
0.01% MUT/WT mix should be also run on each PCR
run, in order to have a reliable indication of the Cq value
of one single copy of the mutant allele. This Cq value
can then be used as a cut-off to distinguish positive am-
plifications from any rare false-positive event.
Results obtained with QuanTAS-PCR were validated
against those obtained with our previously published
ACB-PCR qualitative assay [17]. The ACB-PCR assay was
able to detect as few as 1% mutant alleles, but often
presented some reproducibility problems, i.e. some sam-
ple replicates of the ACB-PCR assay showed ambiguous
or even contrasting results between replicates. In these
cases the ACB-PCR assay had to be repeated in order to
confirm the positivity of those samples. Five clinical sam-
ples that were previously reported as negative for the
V617F mutation when tested by ACB-PCR, were clearly
positive when tested with the more sensitive QuanTAS-
PCR, scoring mutant-allele burdens which ranged from
2.03% to 0.13%. Furthermore, the QuanTAS-PCR gener-
ated similar mutant-allele burden results for each of the
sample triplicates, thus showing very good reproducibility
(Additional file 3).
The QuanTAS-PCR’s quantitative results were also vali-
dated against those obtained with the commercially avail-
able kit “JAK2 MutaQuant” (Ipsogen) which is based on a
dual TaqMan probe allelic discrimination approach. All of
the samples that were determined to have the V617F mu-
tation when tested with QuanTAS-PCR, were then tested
in a blinded fashion with the Ipsogen kit. The two quanti-
tative tests generated comparable mutant-allele burden
values and the resulting values were very well correlated
(Additional file 3).
Conclusions
In this study, we have developed a mutant allele-specific
quantitative PCR assay, with a unique combination of
features; a mutation-specific primer, a 3′ dideoxy blocker,
a PCR specificity enhancer and real time amplification
analysis, which is suitable for minimal residual disease
studies. A recent review concluded that a JAK2 V617F de-
tection assay should be both specific and sensitive enoughto detect a mutant allele burden as low as 1–3% [28].
Thus QuanTAS-PCR is also suitable as a diagnostic
method.
QuanTAS-PCR shows a very high analytical sensitivity
and the ability to efficiently suppress wild-type allele
amplification. We can consistently and reproducibly de-
tect the presence of extremely low levels of JAK2 V617F
in a wild-type allele background, being able to detect as
low as one mutant template per well. When higher num-
bers of replicates are tested, higher sensitivities are
achievable depending on the total number of templates
assessed. The combination of principles in this assay can
thus be used in minimal residual disease monitoring, not
just for JAK2 V617F, but for other common recurrent
single nucleotide mutations in solid tumours, e.g. BRAF
c.1799T > A (V600E) or the acquired resistance mutation
EGFR c.2369C > T (T790M).
Additional files
Additional file 1: The R script used in determining average JAK2
mutant copy number.
Additional file 2: LinRegPCR analysis: background noise increases
as the DNA input per well increases. The JAK2 mutation-specific PCR
amplification curves are shown without baseline correction. A range of
samples containing different percentages of the mutant allele (MUT)
relative to the wild-type allele (WT) were tested (MUT 100%, MUT/WT
30%, MUT/WT 10%, MUT/WT 3%, MUT/WT 1%, MUT/WT 0.3%, MUT/WT
0.1%, MUT/WT 0.03%, MUT/WT 0.01%). The four panels show how the
background noise increases as the DNA input per well increases. Panel A:
33 ng of DNA per well; Panel B: 66 ng of DNA per well; Panel C: 99 ng of
DNA per well. Panel D: 198 ng of DNA per well. The LinRegPCR software
indicated that some of the samples could not be analysed due to high
background noise when 66, 99 or 198 ng of DNA were tested, but this
never occurred when using 33 ng DNA per well. As discussed in the
Results section, we concluded that the optimal amount of DNA to be
assessed per well corresponded to 33 ng (Panel A).
Additional file 3: Validation of QuanTAS-PCR JAK2 assay. The results
from the QuanTAS-PCR assay in comparison with the ACB-PCR assay and
the Ipsogen JAK2 MutaQuant assay. Samples in grey were excluded from
calculating the average score as they were obvious outliers.
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